|Articles|August 1, 2002

Supplements and Featured Publications

  • Measuring Persistency with Drug Therapy in Glaucoma Management
  • Volume 8
  • Issue 10 Suppl

An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

Download PDF: An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

Articles in this issue

over 23 years ago

Measuring Patient Persistency with Drug Therapy Using Methods for the Design and Analysis of Natural History Studies

over 23 years ago

Participating Faculty

over 23 years ago

Introduction

over 23 years ago

Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims Data

over 23 years ago

Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care Setting

over 23 years ago

Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

over 23 years ago

Measuring Persistency and Intraocular Pressure-Controlled Days in Patients Receiving Topical Glaucoma Medications

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs
Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

View more
Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care
AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

View more
Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text